Importer of Controlled Substances Application: Bellwyck Clinical Services, 27633-27634 [2018-12682]
Download as PDF
<![CDATA[
27633
Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices
Dated: May 30, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–12670 Filed 6–12–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Cambrex Charles City
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 13, 2018. Such persons
may also file a written request for a
DATES:
hearing on the application on or before
July 13, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
delegated to the Assistant Administrator
of the DEA Diversion Control Division
(‘‘Assistant Administrator’’) pursuant to
section 7 of 28 CFR part 0, appendix to
subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on March
10, 2018, Cambrex Charles City, 1205
11th Street, Charles City, IA 50616
applied to be registered as an importer
of the following basic classes of
controlled substances:
Controlled substance
Drug code
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....................................................................................................................
Phenylacetone .................................................................................................................................................................
Coca Leaves ....................................................................................................................................................................
Opium, raw ......................................................................................................................................................................
Poppy Straw Concentrate ...............................................................................................................................................
The company plans to import the
listed controlled substances for internal
use, and to manufacture bulk
intermediates for sale to its customers.
Dated: June 6, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–12683 Filed 6–12–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Bellwyck Clinical Services
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
amozie on DSK3GDR082PROD with NOTICES1
DATES:
issuance of the proposed registration on
or before July 13, 2018. Such persons
may also file a written request for a
hearing on the application on or before
July 13, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
Drug code
Amphetamine ........................................................................................................................................................
Methylphenidate ....................................................................................................................................................
Oxycodone ............................................................................................................................................................
18:01 Jun 12, 2018
Jkt 244001
PO 00000
Frm 00096
Fmt 4703
8333
8501
9040
9600
9670
Sfmt 4703
II
II
II
II
II
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on April
4, 2018, Bellwyck Clinical Services,
8946 Global Way, West Chester, OH
45069 applied to be registered as an
importer of the following basic classes
of controlled substances:
Controlled substance
VerDate Sep<11>2014
Schedule
E:\FR\FM\13JNN1.SGM
13JNN1
1100
1724
9143
Schedule
II
II
II
27634
Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices
The company plans to import the
listed controlled substances in dosage
form to conduct clinical trials.
Approval of permit applications will
occur only when the registrant’s activity
is consistent with what is authorized
under to 21 U.S.C.952 (a)(2).
Authorization will not extend to the
import of FDA approved or nonapproved finished dosage forms for
commercial sale.
Dated: June 6, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–12682 Filed 6–12–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Dated: June 6, 2018.
John J. Martin,
Assistant Administrator.
Drug Enforcement Administration
[Docket No. DEA–392]
[FR Doc. 2018–12680 Filed 6–12–18; 8:45 am]
Importer of Controlled Substances
Application: Restek Corporation
ACTION:
BILLING CODE 4410–09–P
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 13, 2018. Such persons
may also file a written request for a
hearing on the application on or before
July 13, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
DATES:
amozie on DSK3GDR082PROD with NOTICES1
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on
February 20, 2018, Restek Corporation,
110 Benner Cr., Bellefonte, PA 16823
applied to be registered as an importer
of the Schedule I controlled substance
Tetrahydrocannibinols (7370).
The company plans to import the
controlled substance in bulk for the
manufacture of analytical reference
material which, in its final form, is an
exempted product.
VerDate Sep<11>2014
18:01 Jun 12, 2018
Jkt 244001
NATIONAL FOUNDATION ON THE
ARTS AND THE HUMANITIES
Meeting of Humanities Panel
National Endowment for the
Humanities.
ACTION: Notice of meeting.
AGENCY:
The National Endowment for
the Humanities will hold six meetings
of the Humanities Panel, a federal
advisory committee, during July 2018.
The purpose of the meetings is for panel
review, discussion, evaluation, and
recommendation of applications for
financial assistance under the National
Foundation on the Arts and Humanities
Act of 1965.
DATES: See SUPPLEMENTARY INFORMATION
for meeting dates. The meetings will
open at 8:30 a.m. and will adjourn by
5:00 p.m. on the dates specified below.
ADDRESSES: The meetings will be held at
Constitution Center at 400 7th Street
SW, Washington, DC 20506, unless
otherwise indicated.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Voyatzis, Committee
Management Officer, 400 7th Street SW,
Room 4060, Washington, DC 20506;
(202) 606–8322; evoyatzis@neh.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to section 10(a)(2) of the Federal
Advisory Committee Act (5 U.S.C.
App.), notice is hereby given of the
following meeting:
1. Date: July 24, 2018. This meeting
will discuss applications on the topics
of American Literature and Studies, the
Arts, and Media, for the Awards for
SUMMARY:
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
Faculty grant program, submitted to the
Division of Research Programs.
2. Date: July 24, 2018. This meeting
will discuss applications on the topics
of Literature, History, and the Arts, for
the NEH-Mellon Fellowships, submitted
to the Division of Research Programs.
3. Date: July 25, 2018. This meeting
will discuss applications on the topics
of Literature, Philosophy, and Religion,
for the Awards for Faculty grant
program, submitted to the Division of
Research Programs.
4. Date: July 26, 2018. This meeting
will discuss applications on the topics
of History and Politics, for the Awards
for Faculty grant program, submitted to
the Division of Research Programs.
5. Date: July 26, 2018. This meeting
will discuss applications for
Fellowships for Advanced Social
Science Research on Japan, submitted to
the Division of Research Programs.
6. Date: July 27, 2018. This meeting
will discuss applications on the topics
of American History and Studies, and
Social Sciences, for the Awards for
Faculty grant program, submitted to the
Division of Research Programs.
Because these meetings will include
review of personal and/or proprietary
financial and commercial information
given in confidence to the agency by
grant applicants, the meetings will be
closed to the public pursuant to sections
552b(c)(4) and 552b(c)(6) of Title 5,
U.S.C., as amended. I have made this
determination pursuant to the authority
granted me by the Chairman’s
Delegation of Authority to Close
Advisory Committee Meetings dated
April 15, 2016.
Dated: June 7, 2018.
Elizabeth Voyatzis,
Committee Management Officer.
[FR Doc. 2018–12653 Filed 6–12–18; 8:45 am]
BILLING CODE 7536–01–P
NUCLEAR REGULATORY
COMMISSION
[Docket Nos. 50–289 and 50–320; NRC–
2018–0115]
Exelon Generation Company, LLC;
Three Mile Island Nuclear Station,
Units 1 and 2; Suspension of Security
Measures in an Emergency or During
Severe Weather
Nuclear Regulatory
Commission.
ACTION: Exemption; issuance.
AGENCY:
The U.S. Nuclear Regulatory
Commission (NRC) is issuing an
exemption from regulatory requirements
in response to an August 1, 2017,
SUMMARY:
E:\FR\FM\13JNN1.SGM
13JNN1
]]>Agencies
[Federal Register Volume 83, Number 114 (Wednesday, June 13, 2018)]
[Notices]
[Pages 27633-27634]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-12682]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Bellwyck Clinical
Services
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before July 13, 2018. Such
persons may also file a written request for a hearing on the
application on or before July 13, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on April
4, 2018, Bellwyck Clinical Services, 8946 Global Way, West Chester, OH
45069 applied to be registered as an importer of the following basic
classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Amphetamine.................... 1100 II
Methylphenidate................ 1724 II
Oxycodone...................... 9143 II
------------------------------------------------------------------------
[[Page 27634]]
The company plans to import the listed controlled substances in
dosage form to conduct clinical trials.
Approval of permit applications will occur only when the
registrant's activity is consistent with what is authorized under to 21
U.S.C.952 (a)(2).
Authorization will not extend to the import of FDA approved or non-
approved finished dosage forms for commercial sale.
Dated: June 6, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-12682 Filed 6-12-18; 8:45 am]
BILLING CODE 4410-09-P
